IdInvest-backed biotech company Prosensa has entered into a strategic partnership with nonprofit organisation CureDuchenne following a $7m investment.

Netherlands-based biopharmaceutical company Prosensa Holdings has received €5m ($7m) from an affiliate of US-based nonprofit organisation CureDuchenne.

Prosensa develops therapeutics to treat genetic disorders. The funding is part of a collaboration to help get experimental medicine smore quickly to patients with duchenne muscular dystrophy, a muscle-wasting childhood disease, and support four drugs currently undergoing clinical trial. 

Prosensa went public last year in an $89.7m initial public offering. It raised $29.8m in 2012 from Allianz-backed investment firm IdInvest Partners, New Enterprise…